The Tenosynovial Giant Cell Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Tenosynovial Giant Cell Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tenosynovial Giant Cell Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tenosynovial Giant Cell Tumor and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Tenosynovial Giant Cell Tumor by ten companies/universities/institutes. The top development phase for Tenosynovial Giant Cell Tumor is phase i with five drugs in that stage. The Tenosynovial Giant Cell Tumor pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Tenosynovial Giant Cell Tumor pipeline products market are: Hutchison MediPharma, Abbisko Therapeutics and Elixiron Immunotherapeutics.
The key targets in the Tenosynovial Giant Cell Tumor pipeline products market include Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1), Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1), and Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1).
The key mechanisms of action in the Tenosynovial Giant Cell Tumor pipeline product include Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Inhibitor with six drugs in Filing rejected/Withdrawn. The Tenosynovial Giant Cell Tumor pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Tenosynovial Giant Cell Tumor pipeline products market including Small Molecule, and Monoclonal Antibody.
Tenosynovial Giant Cell Tumor overview
Tenosynovial Giant Cell Tumors are non-cancerous or benign form of tumors arising from the synovium of the joints or in the soft tissues. Genetically caused due to mutations in the stromal cells of synovium and is divided into three different types as Giant cell tumors of the synovium, Giant cell tumors of the tendon sheath, Giant cell tumors of the bursa. It can develop at any part but commonly affected areas are fingers, thumbs, elbow, ankle, and wrist. It is a rare form diagnosed by MRI. Pain, swelling, bump or lump at the site, pain in joints, and stiffness. Surgical removal of the tumor or radiation therapy are treatment steps.
For a complete picture of Tenosynovial Giant Cell Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
